Amylin reiterated by Merrill at neutral

Amylin Pharmaceuticals Inc. was reiterated by Merrill Lynch analyst Thomas McGahren at a neutral rating following preliminary phase II trial data released by the company, Eli Lilly & Co. and Alkermes Inc. for exenatide LAR in type 2 diabetic patients. Amylin shares Tuesday jumped $6.07, or 27.68%, to close at $28.00 on volume of 32,204,413 shares versus the three-month running average of 3,655,720 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.